| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Miriam J Smith | Q58217715 |
| Nicola Flaum | Q86833662 | ||
| Richard Edmondson | Q89016115 | ||
| Emma J. Crosbie | Q38641940 | ||
| P2093 | author name string | Dafydd G Evans | |
| P2860 | cites work | Improved survival in women with BRCA-associated ovarian carcinoma | Q46693199 |
| Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype | Q47418527 | ||
| Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies | Q47677650 | ||
| Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy. | Q47733105 | ||
| Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. | Q47958061 | ||
| Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. | Q48526678 | ||
| The Icelandic Cancer Project--a population-wide approach to studying cancer. | Q49296931 | ||
| Population based testing of non-mucinous epithelial ovarian cancer in Scotland. | Q49823178 | ||
| Pathology of cancers of the female genital tract. | Q50976133 | ||
| Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds. | Q51624037 | ||
| Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer. | Q52678656 | ||
| Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. | Q53085005 | ||
| Ovarian cancer | Q54105461 | ||
| Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data. | Q54950358 | ||
| Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation | Q56240758 | ||
| Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer | Q56807699 | ||
| RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families | Q57083786 | ||
| Germline RAD51C mutations confer susceptibility to ovarian cancer | Q57266552 | ||
| Polymorphisms in DNA repair genes and epithelial ovarian cancer risk | Q57306195 | ||
| Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies | Q57559806 | ||
| Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations | Q57688855 | ||
| “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations | Q57694467 | ||
| Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | Q57806929 | ||
| A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk | Q59355837 | ||
| Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome. | Q60458159 | ||
| CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors | Q60661770 | ||
| Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1 | Q63183299 | ||
| A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer | Q64004350 | ||
| Landscape of pathogenic variations in a panel of 34 genes and cancer risk estimation from 5131 HBOC families | Q64123868 | ||
| Cancer predisposing BARD1 mutations in breast-ovarian cancer families | Q64386906 | ||
| A systematic review and meta-analysis of family history and risk of ovarian cancer | Q74688260 | ||
| Analysis of CHEK2 gene for ovarian cancer susceptibility | Q80600354 | ||
| Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer | Q83145997 | ||
| Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q86063198 | ||
| Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival | Q87444231 | ||
| The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice | Q88917800 | ||
| Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing | Q91054176 | ||
| Exome Sequencing-Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants | Q91057564 | ||
| BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function | Q24291119 | ||
| Homologous pairing and ring and filament structure formation activities of the human Xrcc2*Rad51D complex | Q24292270 | ||
| Isolation and characterization of RAD51C, a new human member of the RAD51 family of related genes | Q24311195 | ||
| Identification, characterization, and genetic mapping of Rad51d, a new mouse and human RAD51/RecA-related gene | Q24312723 | ||
| A single ataxia telangiectasia gene with a product similar to PI-3 kinase | Q24323579 | ||
| Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing | Q24632270 | ||
| Endometriosis and ovarian cancer: links, risks, and challenges faced | Q27003273 | ||
| Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer | Q27009306 | ||
| The changing view of high-grade serous ovarian cancer | Q27025411 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas | Q27852671 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Worms gang up on bacteria | Q27860588 | ||
| Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy | Q28087741 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| Germline mutations in RAD51D confer susceptibility to ovarian cancer | Q28245028 | ||
| Mutations in BRIP1 confer high risk of ovarian cancer | Q28249514 | ||
| Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population | Q28266112 | ||
| Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene | Q28280022 | ||
| A review of the clinical relevance of mismatch-repair deficiency in ovarian cancer | Q28283356 | ||
| Hallmarks of 'BRCAness' in sporadic cancers | Q29618825 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 | ||
| Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer | Q30252854 | ||
| Inherited Mutations in Women With Ovarian Carcinoma | Q30353433 | ||
| Mucinous ovarian cancer: A therapeutic review. | Q30386967 | ||
| Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center. | Q31149715 | ||
| TP53 mutations in human cancers: origins, consequences, and clinical use | Q33685392 | ||
| Pan-cancer analysis reveals technical artifacts in TCGA germline variant calls | Q33786614 | ||
| Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer | Q33810128 | ||
| Dietary intake and ovarian cancer risk: a systematic review | Q33829249 | ||
| Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy | Q33947083 | ||
| The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population | Q33991747 | ||
| Tubal ligation and the risk of ovarian cancer: review and meta-analysis | Q34126227 | ||
| Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies | Q34273433 | ||
| DNA methylation: an alternative pathway to cancer | Q34290123 | ||
| Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. | Q34334383 | ||
| Hereditary ovarian cancer: not only BRCA 1 and 2 genes. | Q34480707 | ||
| Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. | Q34541051 | ||
| Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers | Q34768542 | ||
| Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis | Q34860429 | ||
| Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management | Q34977063 | ||
| The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers | Q35018746 | ||
| Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies | Q35594488 | ||
| Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence | Q35644167 | ||
| Bilateral salpingectomy can reduce the risk of ovarian cancer in the general population: A meta-analysis. | Q35895748 | ||
| Hereditary ovarian cancer in Ashkenazi Jews | Q35934068 | ||
| Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. | Q35947034 | ||
| Homologous recombination and its regulation | Q36106937 | ||
| BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group | Q36145443 | ||
| Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies | Q36201263 | ||
| Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer | Q36255665 | ||
| Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer | Q36276527 | ||
| Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women | Q36318325 | ||
| Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome | Q36406904 | ||
| Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
| Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis | Q36708188 | ||
| Reproductive factors for ovarian cancer in southern Chinese women | Q36817485 | ||
| RNF138 interacts with RAD51D and is required for DNA interstrand crosslink repair and maintaining chromosome integrity | Q36945532 | ||
| Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers | Q37090813 | ||
| Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery | Q37362164 | ||
| Adherence to Mediterranean diet and risk of cancer: an updated systematic review and meta-analysis of observational studies | Q37441722 | ||
| Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer. | Q37693658 | ||
| Epidemiology of ovarian cancer: a review | Q37720438 | ||
| Alcohol drinking and epithelial ovarian cancer risk. a systematic review and meta-analysis | Q37997178 | ||
| Hereditary gynaecological malignancies: advances in screening and treatment | Q38067433 | ||
| Ovarian cancer: risk factors, treatment and management | Q38143316 | ||
| Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications | Q38170877 | ||
| Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities - a systematic review. | Q38330192 | ||
| Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors | Q38470417 | ||
| A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer | Q38616258 | ||
| BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer | Q38796030 | ||
| Peutz-Jeghers Syndrome: Pathobiology, Pathologic Manifestations, and Suggestions for Recommending Genetic Testing in Pathology Reports | Q38848440 | ||
| Low-grade serous ovarian cancer: A review | Q38942767 | ||
| High-grade serous ovarian cancer: the clone wars. | Q39116957 | ||
| Cascade carrier testing after a child is diagnosed with cystic fibrosis through newborn screening: investigating why most relatives do not have testing | Q39479297 | ||
| Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. | Q39616232 | ||
| Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval | Q39712677 | ||
| Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database | Q40103447 | ||
| The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair | Q40382210 | ||
| Referral of Ovarian Cancer Patients for Genetic Counselling by Oncologists: Need for Improvement | Q40796773 | ||
| HBOC multi-gene panel testing: comparison of two sequencing centers | Q40892042 | ||
| Ovarian cancer: epidemiology and risk factors | Q40999951 | ||
| BRCA population screening for predicting breast cancer: for or against? | Q41050195 | ||
| Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction | Q41195564 | ||
| Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2. | Q41524579 | ||
| Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants | Q44058392 | ||
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study | Q44846367 | ||
| Contributions of ATM mutations to familial breast and ovarian cancer. | Q46062845 | ||
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial | Q46270437 | ||
| Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). | Q46567658 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | ovarian neoplasm | Q11793790 |
| DNA mismatch repair | Q2984243 | ||
| ovarian epithelial carcinoma | Q103839148 | ||
| P304 | page(s) | 54-63 | |
| P577 | publication date | 2019-05-29 | |
| 2020-01-01 | |||
| P1433 | published in | Clinical Genetics | Q5133760 |
| P1476 | title | Epithelial ovarian cancer risk: A review of the current genetic landscape | |
| P478 | volume | 97 |
Search more.